Pain, Postoperative
Conditions
Keywords
Bunionectomy, Bunion surgery, Post-operative pain
Brief summary
A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.
Interventions
25 mg every 6 hours
Placebo every 6 hours
Sponsors
Study design
Eligibility
Inclusion criteria
* 18-65 years of age * Have undergone bunionectomy surgery * Have achieved adequate post-surgical pain
Exclusion criteria
* Confounding medical conditions which preclude study participation * Participated in a study of another investigational drug or device within 30 days prior to randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy | Over 48 hours after bunionectomy | Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug | 8 hours post single dose | — |
| Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug | 8 hours post single dose | — |
| Number of Patients With Perceptible Pain Relief on Day 1 | 8 hours post single dose | Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method. |
| Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1 | 8 hours post single dose | — |
| Number of Patients Who Required Rescue Medication on Day 1 | Day 1 | — |
| Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1 | 8 hours post single dose | — |
| Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug | 8 hours post single dose | Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score. |
| Number of Patients Who Required Rescue Medication on Day 2 | Day 2 | — |
| Number of Patients Who Required Rescue Medication on Day 3 | Day 3 | Day 3 data reflect the use of rescue medication only up to the time of discharge |
| Number of Patients With Meaningful Pain Relief on Day 1 | 8 hours post single dose | Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule 25 mg capsule, every 6 hours | 102 |
| Placebo Oral placebo capsule, every 6 hours | 99 |
| Total | 201 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lack of Efficacy | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Placebo | Total |
|---|---|---|---|
| Age Continuous | 45 years STANDARD_DEVIATION 11 | 45 years STANDARD_DEVIATION 12 | 45 years STANDARD_DEVIATION 11.5 |
| Baseline pain score | 6.9 units on a scale STANDARD_DEVIATION 1.7 | 7.3 units on a scale STANDARD_DEVIATION 1.9 | 7.1 units on a scale STANDARD_DEVIATION 1.8 |
| Race/Ethnicity, Customized Asian | 4 participants | 5 participants | 9 participants |
| Race/Ethnicity, Customized Black | 23 participants | 19 participants | 42 participants |
| Race/Ethnicity, Customized Caucasian | 61 participants | 56 participants | 117 participants |
| Race/Ethnicity, Customized Hispanic | 13 participants | 16 participants | 29 participants |
| Race/Ethnicity, Customized Other | 1 participants | 3 participants | 4 participants |
| Region of Enrollment United States | 102 participants | 99 participants | 201 participants |
| Sex: Female, Male Female | 88 Participants | 86 Participants | 174 Participants |
| Sex: Female, Male Male | 14 Participants | 13 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 21 / 102 | 44 / 99 |
| serious Total, serious adverse events | 0 / 102 | 1 / 99 |
Outcome results
Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy
Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain
Time frame: Over 48 hours after bunionectomy
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy | 2.5 units on a scale | Standard Deviation 2 |
| Placebo | Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy | 5.6 units on a scale | Standard Deviation 2 |
Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1
Time frame: 8 hours post single dose
Population: Number of participants analyzed includes only the number of participants with meaningful pain relief on Day 1 (see previous outcome measure, #4).~Number of patients in the placebo group is intentionally blank as the data was not calculable since less than 50% of the patients reported meaningful relief (ie, median cannot be calculated).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1 | 70.2 minutes |
Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1
Time frame: 8 hours post single dose
Population: Number of participants analyzed includes only the number of participants with perceptible pain relief on Day 1 (see previous Outcome Measure #2)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1 | 26.0 minutes |
| Placebo | Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1 | 22.2 minutes |
Number of Patients Who Required Rescue Medication on Day 1
Time frame: Day 1
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Number of Patients Who Required Rescue Medication on Day 1 | 40 participants |
| Placebo | Number of Patients Who Required Rescue Medication on Day 1 | 87 participants |
Number of Patients Who Required Rescue Medication on Day 2
Time frame: Day 2
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Number of Patients Who Required Rescue Medication on Day 2 | 22 participants |
| Placebo | Number of Patients Who Required Rescue Medication on Day 2 | 64 participants |
Number of Patients Who Required Rescue Medication on Day 3
Day 3 data reflect the use of rescue medication only up to the time of discharge
Time frame: Day 3
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Number of Patients Who Required Rescue Medication on Day 3 | 5 participants |
| Placebo | Number of Patients Who Required Rescue Medication on Day 3 | 29 participants |
Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug
Time frame: 8 hours post single dose
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug | 62 participants |
| Placebo | Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug | 40 participants |
Number of Patients With Meaningful Pain Relief on Day 1
Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.
Time frame: 8 hours post single dose
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Number of Patients With Meaningful Pain Relief on Day 1 | 58 participants |
| Placebo | Number of Patients With Meaningful Pain Relief on Day 1 | 35 participants |
Number of Patients With Perceptible Pain Relief on Day 1
Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.
Time frame: 8 hours post single dose
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Number of Patients With Perceptible Pain Relief on Day 1 | 84 participants |
| Placebo | Number of Patients With Perceptible Pain Relief on Day 1 | 69 participants |
Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug
Time frame: 8 hours post single dose
Population: Number of participants analyzed includes only the number of participants with at least a 30% reduction in pain intensity after the 1st dose (see previous outcome measure, #7).~Number of placebo patients is intentionally blank as the data (eg., upper CI) was not calculable.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug | 60 minutes |
Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug
Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.
Time frame: 8 hours post single dose
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Zipsor (Diclofenac Potassium) Liquid Filled Capsule | Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug | 8.2 units on a scale | Standard Deviation 9.3 |
| Placebo | Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug | 2.6 units on a scale | Standard Deviation 3.9 |